ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
Solara Active Pharma Sciences scheduled a board meeting for May 15, 2026, to approve audited financial results. The trading window remains closed until May 17.
Solara Active Pharma Sciences announced the successful closure of a US FDA inspection at its Puducherry Ibuprofen facility. The inspection, conducted in February 2026, concluded with a 'Voluntary Action Indicated' classification and issuance of an Establishment Inspection Report. The site remains in a state of cGMP compliance, supporting its global API manufacturing strategy.
Solara Active Pharma Sciences Limited has issued a final call notice for ₹134.99 Crore (₹112.50 per share) to holders of partly paid-up rights equity shares. The payment period runs from April 23 to May 07, 2026. Failure to pay will result in the forfeiture of shares and previously paid amounts.